FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement
• By The Tan Sheet
A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
